Evidence map›Paper›PMID 40324947›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026

Kaposi Sarcoma-Associated Herpesvirus Risk and Disease in Kidney Donors and Transplant Recipients With HIV in the United States.

Puja H Nambiar, Tao Liang, Nazzarena Labo, Jonathan Hand, Emily A Blumberg, Meenakshi M Rana, Sander Florman, Brandy Haydel, Michele I Morris, Joanna Schaenman and 29 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. KSHV Seropositivity Associates With Impaired Immune Reconstitution in Virally Suppressed HIV.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Article
  4. Donor-derived viral infections: the usual suspects and the new kids on the block.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Review
  5. Review
  6. HHV-8/KSHV in Solid Organ Transplantation: Current Gaps of Knowledge and Future Directions.Transplant infectious disease : an official journal of the Transplantation Society
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Puja H NambiarDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Tao LiangDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-6355-5546
Nazzarena LaboViral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.ORCID 0000-0001-5953-4064
Jonathan HandDepartment of Medicine, Ochsner Health, New Orleans, Louisiana, USA.ORCID 0000-0002-5752-9576
Emily A BlumbergDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-5193-6170
Meenakshi M RanaDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Sander FlormanRecanati-Miller Transplantation Institute, The Mount Sinai Hospital, New York, New York, USA.
Brandy HaydelRecanati-Miller Transplantation Institute, The Mount Sinai Hospital, New York, New York, USA.ORCID 0000-0002-5039-8526
Michele I MorrisDivision of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.ORCID 0000-0002-4479-8726
Joanna SchaenmanDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Moreno M S RodriguesDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
William A WerbelDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-2943-5895
Mary G BowringDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Rachel J Friedman-MoracoDepartment of Medcine, Emory University, Atlanta, Georgia, USA.
Peter StockDepartment of Surgery, University of California, San Francisco, San Francisco, California, USA.
Valentina StosorDivisions of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0002-0388-5460
Shikha MehtaDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Alexander J GilbertDepartment of Medicine, Georgetown University, Washington District of Columbia, USA.ORCID 0000-0001-5069-1880
Nahel EliasDepartment of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0001-6466-7347
Sapna A MehtaNew York University Langone Transplant Institute, New York, New York, USA.
Catherine B SmallDepartment of Medicine, Weill Cornell Medicine, New York, New York, USA.
Ghady HaidarDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Maricar MalinisSection of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0002-5720-9994
Marcus R PereiraDepartment of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Saima AslamDivision of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA.
David WojciechowskiDepartment of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0001-9170-9338
Ricardo La HozDepartment of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0002-1560-3192
Carlos A Q SantosDivision of Infectious Diseases, Rush University Medical Center, Chicago, Illinois, USA.ORCID 0000-0002-6224-0371
Senu ApewokinDepartment of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Jose A Castillo-LugoDepartment of Medicine, Methodist Health System Clinical Research Institute, Dallas, Texas, USA.
Karthik RangannaDepartment of Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Megan MorsheimerNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Allan MassieNew York University Langone Transplant Institute, New York, New York, USA.ORCID 0000-0002-5288-5125
Dorry L SegevNew York University Langone Transplant Institute, New York, New York, USA.ORCID 0000-0002-1924-4801
Wendell MileyViral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Vickie MarshallViral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.ORCID 0000-0002-4069-185X
Denise WhitbyViral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.ORCID 0000-0002-7407-2563
Aaron A A TobianDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Christine M DurandDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-2605-9257

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
HOPE in Action: A Clinical Trial of HIV-to-HIV Liver TransplantationU01AI138897 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Christine Marie Durand, DORRY L. SEGEV · 2018 to 2026
$25.5M
Kidney Transplantation from Donors with HIV: Impact on Rejection and Long-term OutcomesU01AI177211 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Christine Marie Durand, DORRY L. SEGEV · 2023 to 2026
$6.9M
Unlocking the Potential of HIV-Infected Deceased Donors for Organ TransplantationR01AI120938 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TOBIAN, AARON A · 2016 to 2021
$4.3M
T-cell depletion and maintenance of the HIV-1 latent reservoir in distinct tissue compartmentsR01DK131926 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI Melissa Laird Smith, AARON A TOBIAN · 2022 to 2026
$3.6M
The Landscape of Serious Infections following Kidney Transplantation in People Living with HIVK23AI157893 · NIAID · JOHNS HOPKINS UNIVERSITY · PI WERBEL, WILLIAM · 2021 to 2025
$847k
Leveraging a novel health records platform to predict the development of cardiovascular disease following kidney transplantationF30HL168842 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BOWRING, MARY GRACE · 2023 to 2025
$170k
Johns Hopkins School of Medicine Discovery Fund for SynergyNCI NIH HHS P30 CA008748NHLBI NIH HHS F30 HL168842NIAID NIH HHS K23 AI157893NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI120938NIAID NIH HHS U01 AI138897NIAID NIH HHS U01 AI177211NIDDK NIH HHS R01 DK131926NIH HHS K23AI157893NIH HHS K24 AI144952NIH HHS R01AI120938NIH HHS R01DK131926NIH HHS U01 AI138897NIH HHS U01AI177211The Living Legacy Foundation 75N91024F00011
6 · The paper itself

Abstract

backgroundDue to high prevalence of Kaposi sarcoma-associated herpesvirus (KSHV) among people with human immunodeficiency virus (HIV), KSHV-associated disease (KAD) may be increased after kidney transplantation from donors with HIV (HIV D+) to recipients with HIV (HIV R+).

methodsAnti-KSHV antibodies were measured in HIV R+ and donors with and without HIV (HIV D-) using a 30-antigen multiplex assay within 3 multicenter kidney transplantation studies. KSHV seropositivity was defined as reactivity to conventional KSHV antigens (≥1 ORF73 or K8.1); reactivity to expanded 5-antigen and 30-antigen panels were also reported. Risk factors were identified using modified Poisson regression. Recipients were monitored for posttransplant anti-KSHV antibody changes and KAD.

resultsKSHV seroprevalence was 40.6% (143/352) among HIV R+, 25.2% (33/131) among HIV D+, and 7.5% (4/53) among HIV D-. In the multivariable model, only men who have sex with men (MSM) status was associated with KSHV seropositivity (relative risk, 1.51 [95% confidence interval {CI}, 1.07-2.14] in recipients and 2.39 [95% CI, 1.03-5.53] in donors). Among 418 HIV R+ (215 HIV D+/R+, 203 HIV D-/R+), there were 5 KAD cases (incidence, 0.63 cases/100 person-years [95% CI, .26-1.52]): 3 skin-only Kaposi sarcoma (KS), 1 multicentric Castleman disease, and 1 allograft KS. The allograft KS occurred in a female HIV D+/R+ and was likely donor derived. Remaining KAD cases occurred in male HIV D-/R+ and were likely recipient KSHV reactivation or acquisition.

conclusionsIn the United States, KSHV seroprevalence in donors and recipients with HIV was high, particularly among MSM. Reassuringly, KSHV-associated disease was rare and primarily attributed to recipient rather than donor-derived KSHV.

Indexed as

Herpesviridae InfectionsHerpesvirus 8, HumanHIV InfectionsKidney TransplantationSarcoma, KaposiTissue DonorsTransplant RecipientsAdultAntibodies, ViralFemaleHumansMaleMiddle AgedRisk FactorsSeroepidemiologic StudiesUnited StatesAntibodies, ViralHIVHOPE Acthuman herpesvirus 8Kaposi sarcomaKSHV seroprevalence

Identifiers

PMID40324947
PMCPMC13110356

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.